Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

5823 - Pulmonary tumor-draining vein exosomal lincRNA-p21 levels impacts non-small cell lung cancer prognosis


28 Sep 2019


Poster Display session 1


Tumour Site

Non-Small Cell Lung Cancer


Joan Castellano


Annals of Oncology (2019) 30 (suppl_5): v585-v590. 10.1093/annonc/mdz258


J.J. Castellano1, A. Navarro1, L. Molins2, J. Canals1, R. Marrades3, N. Viñolas4, J. Moises3, M. Casadevall1, Y. Li1, B. Han1, D. Martinez4, J. Martin1, A. Garisoain1, C. Muñoz1, J. Ramirez5, M. Monzo1

Author affiliations

  • 1 Human Anatomy, Univeristy of Barcelona, School of Medicine, 08028 - Barcelona/ES
  • 2 Thoracic Surgery, Hospital Clinic of Barcelona, 08036 - Barcelona/ES
  • 3 Pneumology, Hospital Clinic of Barcelona, 08036 - Barcelona/ES
  • 4 Dept. Medical Oncology, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES
  • 5 Pathology, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5823


In resected non-small cell lung cancer (NSCLC) considerable recurrence rates has been reported (30%). Tumor secretes small extracellular vesicles known as exosomes, which plays a role in the metastasis process. Pulmonary tumor-draining vein blood has proved to be better source than peripheral vein to analyze the prognosis impact of exosomes (Navarro A, et al. Cancers 2019). LincRNA-p21 is a long non-coding RNA which upregulation in tumor tissue induced by hypoxia was related to poor prognosis in NSCLC (Castellano JJ. et al. JTO 2016). We aimed to evaluate the presence of lincRNA-p21 in exosomes and its potential as prognosis biomarker in resected NSCLC patients.


H23 and H1299 NSCLC cell lines were cultured in exosome-free medium 48h under normoxic/hypoxic conditions. LincRNA-p21 was inhibited using a siRNA and quantified using a TaqMan assay. Exosomes were purified by ultracentrifugation and characterized by electron microscopy, western blot and Nanosight. LincRNA-p21 was analyzed in exosomes from pulmonary tumor-draining vein, obtained during surgery, from 54 NSCLC patients.


LincRNA-p21 was present in exosomes showing 18 times more representation than in their origin cells. Under hypoxic conditions exosomal lincRNA-p21 was upregulated in both cell lines (p < 0.05). Cellular lincRNA-p21 silencing resulted in a reduction in exosomal lincRNA-p21 (p = 0.04) indicating a relation between cellular and exosomal levels. The analysis in patient samples showed that lincRNA-p21 was present in patient exosomes obtained from tumor-draining vein. The survival analysis showed that high exosomal lincRNA-p21 levels were associated with shorter time to relapse (TTR) (37 vs 56 months; p = 0.03) and shorter overall survival (OS) (46 vs 66 months; p = 0.04). In the multivariate analysis exosomal lincRNA-p21 emerged as an independent prognostic marker for TTR (HR: 3.1; 95%CI: 1.02-9.4; p = 0.04) and OS (HR: 5.3; 95%CI: 1.6-17.2; p = 0.006) together with disease stage.


Tumor exosomes carry LincRNA-p21, which increases under hypoxia, and its analysis in tumor-draining vein arises as a promising prognosis marker.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


SAF2017-88606-P (AEI/FEDER, UE).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.